Table 1.
Demographics among patients with and without “late” diagnosis of HCV*
| Demographics | With late diagnosis* n=1056 (17%) n (%) |
Without late diagnosis n=5117 (83%) n (%) |
OR (95%CI) | ** p-value | |
|---|---|---|---|---|---|
| Age at HCV diagnosis | Mean (median) | 54 (54) | 47 (48) | ||
| Birth cohort | Born after 1965 | 83 (6.6) | 1181 (93.4) | 0.49 (0.37–0.65) | <0.001 |
| Born during1945–1965 | 794 (18.5) | 3500 (81.5) | ref. | ||
| Born before 1945 | 179 (29.1) | 436 (70.9) | 1.34 (1.05–1.72) | 0.02 2-sided t-test for trend, p<.0001 |
|
| Sex | Female | 684 (19.4) | 2881 (80.8) | ref. | |
| Male | 372 (14.3) | 2236 (85.7) | 1.15 (0.98–1.35) | 0.084 | |
| Race | White | 522 (13.8) | 3255 (86.2) | ref. | |
| Black | 399 (25.0) | 1200 (75.0) | 1.52 (1.26–1.82) | <0.001 | |
| Asian | 30 (14.4) | 179 (85.6) | 0.85 (0.54–1.34) | 0.849 | |
| Hawaiian/PI | 19 (16.0) | 100 (84.0) | 0.93 (0.51–1.69) | 0.614 | |
| American Indian/Alaska Native | 12 (16.7) | 60 (83.3) | 1.67 (0.82–3.39) | 0.213 | |
| Unknown | 74 (18.6) | 323 (81.4) | 1.45 (1.01–2.06) | 0.116 | |
| Hispanic ethnicity | 32 (15.2) | 179 (84.8) | 0.8 (0.49–1.28) | 0.355 | |
| Household income† | <15,000 | 112 (14) | 661 (86) | 1.35 (0.99–1.83) | 0.059 |
| 15,000–29,000 | 250 (22) | 909 (78) | 1.08 (0.84–1.39) | 0.554 | |
| 30,000–49,000 | 443 (12) | 2167 (88) | 1.03 (0.84–1.28) | 0.758 | |
| 50,000–75,000 | 198 (16) | 1040 (84) | ref. | ||
| >75,000 | 40 (14) | 239 (86) | 0.80 (0.53–1.21) | 0.292 | |
| Insurance | None | 40 (20.4) | 156 (79.6) | 1.47 (0.95–2.27) | 0.082 |
| Medicaid | 152 (16.3) | 783 (83.7) | 1.44 (1.14–1.83) | 0.003 | |
| Medicare only | 154 (24.5) | 475 (75.5) | 1.32 (1.03–1.70) | 0.028 | |
| Medicare Plus | 250 (26.3) | 701 (73.7) | 1.49 (1.19–1.86) | 0.001 | |
| Private | 437 (13.2) | 2883 (86.8) | ref. |
Late diagnosis defined as having either a biopsy indicating fibrosis or a FIB-4 score >5.88 8,9 during the time period from three months prior up to twelve months post initial HCV diagnosis, or: during the time period from prior to up to twelve months post initial HCV diagnosis having an ICD9 diagnosis or procedure code indicating liver transplant (996.82, 50.5, 50.51, 50.59, 47135, 47136), hepatocellular carcinoma (155.0 155.1 155.2), liver failure (572.4), hepatic encephalopathy (572.2), portal hypertension (572.3, 37140, 37160, 37180, 37181, 37182, 37183), esophageal varices (456.0, 456.20, 43204, 43205, 43243, 43244, 43400, 43401, 42.91, 44.91, 96.06), other gastroesophageal hemorrhage (530.7, 530.82, 578.0, 578.1, 578.9), ascites (789.5, 789.59, 49080, 49081, 54.91), or other sequelae of chronic liver disease (572.8).
SAS (SAS Institute Inc. Cary, North Carolina, USA) procedure GENMOD was applied to calculate odds ratios adjusted for birth cohort, sex, race, Hispanic ethnicity, geocensus tract estimated household income and health insurance with 95% confidence intervals and Wald Chi-Square test to calculate p-values. For the test of trend a two-sided Cochran-Armitage trend test was applied.
Yearly household income estimated from census tract geocode